Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC-Generated Rx Script Volume Remains Flat - 1999 Prevention Survey

Executive Summary

The percentage of consumers who received a prescription as a result of direct-to-consumer advertising has not changed in the past year, Prevention magazine's 1999 DTC survey reveals.

You may also be interested in...



Direct-To-Consumer Ad Response Kit Proposed By Insurers Group

The National Association of Health Underwriters wants to develop patient education materials to help balance the demand for brand-name drugs created by direct-to-consumer advertising.

Direct-To-Consumer Ad Response Kit Proposed By Insurers Group

The National Association of Health Underwriters wants to develop patient education materials to help balance the demand for brand-name drugs created by direct-to-consumer advertising.

Glaxo Zyban/Wellbutrin DTC Accounts Move To Grey Advertising

The award of Glaxo's bupropion franchise to Grey Advertising consolidates six of the firm's nine DTC-advertised products into one agency.

Related Content

UsernamePublicRestriction

Register

PS034911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel